Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.

Clinical Rheumatology
Susanne Juhl PedersenJulia Sidenius Johansen

Abstract

The objectives of the study were to investigate short and long-term changes and relations to treatment response of plasma interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), YKL-40, matrix metalloproteinase-3 (MMP-3), and total aggrecan in patients with spondyloarthritis (SpA) treated with tumor necrosis factor-alpha (TNFα) inhibitors and to compare with levels in healthy subjects. Biomarkers were measured in an observational cohort of 49 SpA patients (ankylosing spondylitis, n=32, and psoriatic arthritis, n=17) initiating TNFα inhibitor therapy (infliximab, n=38; etanercept, n=8; and adalimumab, n=3) and compared with levels in healthy subjects. Clinical parameters and biomarkers were measured at baseline, weeks 2, 6, and every 6-12 weeks for up to 3 years. Patients with co-morbidities (n=4), missing baseline samples (n=3), and adverse events (n=5) were excluded. Patients with SpA had compared with healthy subjects elevated IL-6 (median 8.5 ng/l (range, 0.98-64) vs. 1.3 (0.33-26)), VEGF (105 ng/l (22-752) vs. 45 (12-351)), YKL-40 (74 μg/l (14-572) vs. 43 (20-184)), and MMP-3 (43 μg/l (9.1-401) vs. 16 (2.5-47), p≤0.001), whereas total aggrecan was lower (662 μg/l (223-2,219) vs. 816 (399-2,190), p≤0.001). Two weeks...Continue Reading

References

Oct 17, 2002·Annals of the Rheumatic Diseases·J SieperA Zink
Feb 15, 2005·Annals of the Rheumatic Diseases·D D GladmanP Nash
Dec 6, 2005·Arthritis and Rheumatism·Elli KruithofDominique Baeten
Jul 18, 2006·Joint, Bone, Spine : Revue Du Rhumatisme·Thao PhamUNKNOWN Société Française de Rhumatologie (SFR)
Apr 25, 2007·Scandinavian Journal of Rheumatology·O B PedersenP Junker
Sep 2, 2008·Arthritis and Rheumatism·Jürgen BraunUNKNOWN Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group
Feb 3, 2009·Arthritis Research & Therapy·Walter P Maksymowych
May 5, 2009·The Journal of Rheumatology·Ben DijkmansJoseph Wajdula

❮ Previous
Next ❯

Citations

Aug 16, 2014·Biomarkers in Medicine·Anne S SiebuhrAnne C Bay-Jensen
Oct 1, 2013·Expert Opinion on Biological Therapy·Denis Poddubnyy, Martin Rudwaleit
Jul 16, 2015·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Marketa HusakovaKarel Pavelka
Jan 30, 2016·Expert Review of Clinical Immunology·Elena GeneraliCarlo Selmi
Oct 6, 2016·Expert Review of Clinical Immunology·Maureen C TurinaDominique Baeten
Sep 30, 2016·Annals of Medicine·Anna NeveFrancesco Paolo Cantatore
Nov 5, 2014·The Journal of Rheumatology·Deepak R JadonRaj Sengupta
Feb 27, 2019·International journal for vitamin and nutrition research. Internationale Zeitschrift für Vitamin- und Ernährungsforschung. Journal international de vitaminologie et de nutrition·Ummugulsum CanBahauddin Taha Hidayetoglu
Oct 10, 2018·Therapeutic Drug Monitoring·Erwin Dreesen, Ann Gils
Sep 19, 2017·Expert Review of Molecular Diagnostics·Walter P Maksymowych
Jul 9, 2020·Therapeutic Advances in Musculoskeletal Disease·Mariagrazia LorenzinRoberta Ramonda
Jun 7, 2015·Expert Review of Clinical Immunology·Juergen BraunXenofon Baraliakos
Oct 16, 2015·International Journal of Rheumatic Diseases·Abhijeet Danve, James O'Dell
Mar 19, 2019·Therapeutic Drug Monitoring·Erwin Dreesen, Ann Gils
Oct 12, 2018·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·L TorresH Forsblad-d'Elia
Oct 23, 2013·Experimental Biology and Medicine·Roberta RamondaLeonardo Punzi
Oct 8, 2020·Nature Reviews. Rheumatology·Deepak R JadonOliver FitzGerald
Feb 25, 2021·Expert Review of Clinical Immunology·Ikram MezghicheElisabetta Bianchi
Jun 3, 2021·International Journal of Molecular Sciences·Thi Hong Van Le, Sang-Mo Kwon
May 18, 2021·Therapeutic Advances in Musculoskeletal Disease·Conor MageeDeepak R Jadon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.